CStone Pharmaceuticals · TRADEGATE:PH4

CStone Pharmaceuticals financial statements

CStone Pharmaceuticals's income statement, balance sheet and cash flow, annual and quarterly, each figure dated and linked to the filing it was read from.

Financials

Annual, in CNY

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue269.6M407.2M463.8M481.4M243.7M1.04B012.6M10.3M0
Cost of revenue218.3M167.1M159.5M203.0M106.8M241.4M000
Gross profit51.2M240.2M304.3M278.4M136.9M797.4M12.6M10.3M0
Research and development311.5M134.7M527.8M614.2M1.30B1.40B1.40B850.2M213.4M247.1M
Selling, general and administrative87.3M33.2M48.7M63.2M109.2M86.7M338.6M191.0M39.3M15.1M
Operating income-432.6M-91.7M-605.6M-912.1M-1.83B-1.09B-1.74B-1.03B-242.5M-262.2M
Depreciation and amortization44.0M49.8M58.2M44.5M22.7M14.8M11.6M5.27M823.4K69.0K
EBITDA-388.6M-41.9M-547.4M-867.6M-1.81B-1.08B-1.73B-1.02B-241.7M-262.1M
Interest expense12.9M15.2M11.8M8.48M2.24M1.32M303.0K745.6M60.0K240.0K
Income before tax-423.9M-91.2M-367.2M-902.7M-1.92B-1.22B-2.31B-1.79B-342.5M-253.0M
Income tax13.1M61.9M67.3M-1.10M748.4M-734.0M00
Net income-437.0M-91.2M-367.2M-902.7M-1.92B-1.22B-2.31B-1.75B-308.9M-246.1M
Earnings per share, basic-0.31-0.07-0.29-0.77-1.65-1.04-2.34-1.77-0.31-0.25

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents754.0M387.9M996.7M558.7M742.7M3.02B1.13B701.3M83.4M59.5M
Short-term investments165.1M285.0M51.9M483.4M983.6M369.0M1.62B856.6M454.3M752.4M
Receivables33.8M130.9M172.4M77.1M117.6M0760.0K
Inventory116.9M286.1M108.8M22.2M61.4M0
Current assets1.11B1.09B1.33B1.25B1.96B3.57B2.89B1.60B545.3M824.8M
Property, plant and equipment130.5M153.4M206.6M182.8M102.0M18.7M14.5M15.5M1.03M
Total assets1.36B1.39B1.66B1.64B2.27B3.76B2.95B1.63B564.3M826.1M
Accounts payable77.2M338.0M246.4M290.4M414.3M28.0M37.3M4.56M302.0K
Current liabilities510.4M682.0M850.3M946.5M932.9M727.0M458.0M1.11B113.2M59.2M
Long-term debt156.5M257.4M213.0M219.0M115.8M54.3M
Total debt348.7M356.0M363.4M286.3M174.2M75.2M1.62B
Total liabilities741.6M1.03B1.21B1.19B1.06B808.3M469.1M1.12B113.2M59.2M
Shareholders' equity617.0M363.9M456.8M449.3M1.21B2.95B2.48B515.3M426.3M712.7M
Shares outstanding1.39B1.28B1.26B1.17B1.17B1.17B984.5M984.1M984.1M984.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-327.7M-343.2M-588.8M-612.5M-1.48B-508.1M-1.08B-791.1M-240.2M-213.0M
Capital spending00-65.0M-101.8M-149.1M-71.4M-10.4M-7.91M-12.5M-1.11M
Free cash flow-327.7M-343.2M-653.9M-714.3M-1.63B-579.5M-1.09B-799.0M-252.7M-214.1M
Cash from investing134.0M-247.7M619.6M365.1M-826.6M1.18B-658.9M-377.7M268.3M-753.5M
Cash from financing577.8M-12.9M388.4M28.5M92.3M1.39B2.09B1.66B-300.0K1.01B
Share buybacks74.0K341.8M2.53M16.8M-21.8M2.20B1.66B0706.5M
Change in cash365.8M-608.7M438.0M-184.0M-2.28B1.90B425.1M617.9M23.9M59.5M